These data confirmed the report from 2020 ESMO Open that KEAP1, as well as the STK11, were the prognostic but not predictive biomarkers of immunotherapy or chemotherapy in NSCLC. The gene discussed is KEAP1; the disease is non-small cell lung carcinoma.